Differential regulation of doxorubicin-induced mitochondrial dysfunction and apoptosis by Bcl-2 in mammary (MTLn3) cells by Huigsloot, M. et al.
Differential Regulation of Doxorubicin-induced Mitochondrial
Dysfunction and Apoptosis by Bcl-2 in Mammary Adenocarcinoma
(MTLn3) Cells*
Received for publication, January 14, 2002, and in revised form, June 25, 2002
Published, JBC Papers in Press, July 9, 2002, DOI 10.1074/jbc.M200378200
Merei Huigsloot, Ine B. Tijdens, Gerard J. Mulder, and Bob van de Water‡
From the Division of Toxicology, Leiden Amsterdam Center for Drug Research, Leiden University,
Leiden 2300, The Netherlands
Various anticancer drugs cause mitochondrial pertur-
bations in association with apoptosis. Here we investi-
gated the involvement of caspase- and Bcl-2-dependent
pathways in doxorubicin-induced mitochondrial per-
turbations and apoptosis. For this purpose, we set up a
novel three-color flow cytometric assay using rhoda-
mine 123, annexin V-allophycocyanin, and propidium
iodide to assess the involvement of the mitochondria in
apoptosis caused by doxorubicin in the breast cancer
cell line MTLn3. Doxorubicin-induced apoptosis was
preceded by up-regulation of CD95 and CD95L and a
collapse of mitochondrial membrane potential () oc-
curring prior to phosphatidylserine externalization.
This drop in  was independent of caspase activity,
since benzyloxycarbonyl-Val-Ala-DL-Asp-fluoromethyl-
ketone did not inhibit it. Benzyloxycarbonyl-Val-Ala-DL-
Asp-fluoromethylketone also blocked activation of
caspase-8, thus excluding an involvement of the death
receptor pathway in  dissipation. Furthermore, al-
though overexpression of Bcl-2 in MTLn3 cells inhibited
apoptosis, dissipation of  was still observed. No de-
crease in  was observed in cells undergoing etopo-
side-induced apoptosis. Immunofluorescent analysis of
 and cytochrome c localization on a cell-to-cell basis
indicates that the collapse of  and cytochrome c re-
lease are mutually independent in both normal and Bcl-
2-overexpressing cells. Together, these data indicate
that doxorubicin-induced dissipation of the mitochon-
drial membrane potential precedes phosphatidylserine
externalization and is independent of a caspase- or Bcl-
2-controlled checkpoint.
Upon anticancer drug treatment, a number of cellular stress
response pathways are activated. Some of these pathways are
linked to mitochondrial perturbations that are often associated
with apoptosis. Thus, the release of proapoptotic factors from
the intermembrane space into the cytosol, including cyto-
chrome c, apoptosis-inducing factor, and Smac/DIABLO, occurs
after cytostatic treatment (1–4). The mechanisms regulating
the release of cytochrome c include specific pore formation in
the outer mitochondrial membrane and opening of the perme-
ability transition pore (reviewed in Ref. 5). As a consequence of
both the loss of the electrochemical gradient caused by pore
opening and rupture of the outer mitochondrial membrane, the
mitochondrial membrane potential ()1 generally collapses.
There is general agreement that cytosolic cytochrome c inter-
acts with Apaf-1, ATP, and procaspase-9, resulting in the acti-
vation of the latter, followed by caspase-3 activation and initi-
ation of a proteolytic cascade (6). However, the exact sequence
of events resulting in disruption of mitochondrial function and
release of cytochrome c from the mitochondria in apoptosis
caused by anticancer drugs is not yet clear.
There are two prominent pathways that may cause mito-
chondrial dysfunction during apoptosis. First, death receptor
activation through CD95/CD95L and caspase-8 activation dur-
ing apoptosis is under several circumstances upstream from
mitochondrial perturbations. Thus, active caspase-8 may cause
cleavage of the proapoptotic Bcl-2 member Bid and, as a con-
sequence, mitochondrial dysfunction (7–9). Several anticancer
agents, including doxorubicin and etoposide, can up-regulate
CD95 and CD95L (10–12). However, there is controversy on
the relative importance of this pathway in anticancer drug-
induced mitochondrial perturbations and apoptosis. Thus, in
some cell types, inhibition of this pathway using either Fas-
linked interleukin--converting enzyme inhibitory protein,
CrmA, or dominant negative Fas-associated death domain ab-
rogates apoptosis, whereas in other cell types little effect was
observed (reviewed in Ref. 12). Although up-regulation of death
receptor pathway components was found in some solid tumor
cell lines, the extent of subsequent involvement of the mito-
chondrial pathway remains unclear (11, 13). Up-regulation
and/or translocation of Bax and/or other proapoptotic Bcl-2
family members to the mitochondria is a second major pathway
for mitochondrial perturbation preceding the onset of apopto-
sis. At the mitochondria, Bax invokes cytochrome c release and
loss of  (14), possibly via direct pore formation (15, 16) or by
association with the voltage-dependent anion channel (17, 18).
Importantly, the antiapoptotic Bcl-2 family members Bcl-2 and
Bcl-xL generally inhibit these mitochondrial perturbations (19,
20). Various tumor cells have increased expression of proteins
that inhibit either the death receptor pathways (e.g. Fas-linked
interleukin--converting enzyme inhibitory protein) or apopto-
sis caused by Bax (e.g. Bcl-2 or Bcl-xL) (21–25). These tumor
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cells are generally more resistant to anticancer drug-induced
apoptosis. It is unclear whether such resistance includes mito-
chondrial protection. Therefore, we have investigated the rel-
ative roles of caspase activation and Bcl-2-dependent pathways
in mitochondrial perturbations and apoptosis caused by the
anticancer drug doxorubicin.
Doxorubicin is often used in the treatment of solid tumors,
including breast, liver, and bone tumors (26). It causes DNA
damage and formation of reactive oxygen species, eventually
resulting in apoptosis (27). Although doxorubicin causes mito-
chondrial injury in cardiac muscle cells (28) and some other cell
types, these effects were studied primarily in lymphoid cells
(29, 30). The molecular mechanism of mitochondrial injury and
its role in the induction of apoptosis in adenocarcinoma cells
remains, however, largely unclear. As discussed above, the
dissipation of  is one of the markers for mitochondrial in-
volvement in apoptosis. So far, dissipation of  caused by
doxorubicin has been determined either in the total cell popu-
lation (30–32) or in “viable” cells based on scatter properties
(33). These methods do not allow proper distinction of the exact
cell population in which the changes in  occurred: genuinely
viable, apoptotic or (secondary) necrotic cells. As a conse-
quence, the identification of the exact sequence of events in
doxorubicin-induced apoptosis was precluded. In the present
study, we set up three-color flow cytometry with rhodamine
123, annexin V-allophycocyanin (APC), and propidium iodide
to assess the involvement of the mitochondria in doxorubicin-
induced apoptosis. For this purpose, we used the rat mammary
adenocarcinoma cell line MTLn3, which is often used as a
model to study molecular mechanisms of metastasis formation
(34, 35) and responses to drug therapy both in vitro and in vivo
(36–38). We have previously characterized in detail the induc-
tion of apoptosis by anticancer drugs in these cells (38).
In the present study, we show that the doxorubicin-mediated
collapse of  is a primary event preceding PS externalization.
Moreover, despite the fact that doxorubicin causes up-regula-
tion of CD95 and CD95L, prevention of caspase-8 activation
does not prevent loss of . Furthermore, although Bcl-2 in-
hibits apoptosis, dissipation of  is still observed. Analysis of
 and cytochrome c localization on a cell-to-cell basis indicates
that the collapse of  and cytochrome c release are mutually
independent in both normal and Bcl-2-overexpressing cells.
Together, these data indicate that doxorubicin-induced dissi-
pation of the mitochondrial membrane potential precedes PS
externalization and is independent of a caspase- or Bcl-2-con-
trolled checkpoint.
EXPERIMENTAL PROCEDURES
Chemicals—-Modified minimal essential medium with ribonucleo-
sides and deoxyribonucleosides (-MEM), fetal bovine serum (FBS),
penicillin/streptomycin, LipofectAMINE Plus, and Geneticin (G418 sul-
fate) were from Invitrogen. Collagen (type I, rat tail) was from Upstate
Biotechnology, Inc. (Lake Placid, NY). Doxorubicin, propidium iodide
(PI), 7-amino-4-methylcoumarin (AMC), DiOC6, rhodamine 123, and
RNase A were from Sigma. Benzyloxycarbonyl-Val-Ala-DL-Asp-fluorom-
ethylketone (zVAD-fmk) and acetyl-Asp-Glu-Val-Asp-7-amino-4-meth-
ylcoumarin were from Bachem (Bubendorf, Switzerland). Annexin V
was from Roche Molecular Biochemicals. Hoechst 33258, the AlexaTM
488 protein labeling kit, and MitotrackerTM Red CMXRos were from
Molecular Probes (Leiden, The Netherlands). APC was from Prozyme
(San Leandro, CA). All other chemicals were of analytical grade.
Cell Culture—MTLn3 rat mammary adenocarcinoma cells were orig-
inally developed by Dr. D. R. Welch (Jake Gittlen Cancer Research
Institute, The Pennsylvania State University College of Medicine,
Hershey, PA) and used between passages 46 and 56. They were cul-
tured in -MEM supplemented with 5% (v/v) FBS (complete medium).
For experiments, cells were plated at a density of 4  103 cells/cm2 in
Corning plates (Acton, MA) and grown for 3 days in complete medium
supplemented with 50 units of penicillin/liter and 50 mg of streptomy-
cin/liter (penicillin/streptomycin). Cells were exposed to doxorubicin for
1 h in Hanks’ balanced salt solution (137 mM NaCl, 5 mM KCl, 0.8 mM
MgSO47H2O, 0.4 mM Na2HPO42H2O, 0.4 mM KH2PO4, 1.3 mM CaCl2,
4 mM NaHCO3, 25 mM HEPES, 5 mM D-glucose, pH 7.4). After removal
of doxorubicin, cells were recovered in -MEM containing 2.5% (v/v)
FBS and penicillin/streptomycin for the indicated periods. In some
experiments, cells were recovered in -MEM containing 2.5% (v/v) FBS,
penicillin/streptomycin and 100 M zVAD-fmk.
Construction of Bcl-2-overexpressing Cells—Subconfluent MTLn3
cells were transfected with pcDNA3 (Neo) or pcDNA3 containing hu-
man Bcl-2 (gift from Dr. James L. Stevens) using LipofectAMINE Plus
reagent, and after reaching confluence they were selected for neomycin
resistance (G418; 100 g/ml). For both vectors, three clones were se-
lected and used for up to six passages, during which they stably ex-
pressed Bcl-2 in over 95% of cells based on immunofluorescence.
In some experiments, we used porcine renal proximal tubular cell
line LLC-PK1 expressing either Bcl-2 (pkBCL-2 clone 6) or the empty
vector (pkNEO clone 1) that have been described previously (39). LLC-
PK1 cells were cultured in Dulbecco’s modified Eagle’s medium contain-
ing 10% (v/v) FBS and penicillin/streptomycin. For experiments, cells
were plated overnight in Dulbecco’s modified Eagle’s medium plus
penicillin/streptomycin without FBS on collagen-coated 6-cm culture
dishes to form a subconfluent monolayer as described previously (40).
Thereafter, cells were treated with varying concentrations of doxorubi-
cin in Dulbecco’s modified Eagle’s medium/penicillin/streptomycin for
24 h.
Determination of Cell Death—For annexin V/propidium iodide (AV/
PI) staining, cells were washed twice in PBS (137 mM NaCl, 2.7 mM KCl,
4.3 mM Na2HPO42H2O, 1.4 mM KH2PO4, pH 7.4) containing 1 mM
EDTA (PBS-EDTA) and subsequently trypsinized with 0.13 g/liter tryp-
sin in PBS-EDTA. Medium, washes, and cells were combined and
centrifuged (5 min, 200  g, 4 °C), and the pellet was washed once with
PBS-EDTA. Cells were allowed to recover from trypsinization in com-
plete medium (30 min, 37 °C). Externalized phosphatidylserine (PS)
was labeled (15 min, 0 °C) with AlexaTM 488-conjugated annexin V in
AV buffer (10 mM HEPES, 145 mM NaCl, 5 mM KCl, 1.0 mM
MgCl26H2O, 1.8 mM CaCl22H2O, pH 7.4). Propidium iodide (2 M) in
AV buffer was added 1 min prior to analysis on a FACScalibur flow
cytometer (BD PharMingen).
For cell cycle analysis, trypsinized and floating cells were pooled,
washed with PBS-EDTA, and fixated in 70% (v/v) ethanol (30 min,
20 °C). After two washes with PBS-EDTA, cells were incubated with
PBS-EDTA containing 50 g/ml RNase A and 7.5 M PI (45 min, room
temperature) and subsequently analyzed by flow cytometry.
Caspase-3-like activity was determined as described previously (38).
Briefly, cells were trypsinized as described for AV/PI, washed once in
PBS-EDTA, and resuspended in lysis buffer (10 mM HEPES, 40 mM
-glycerophosphate, 50 mM NaCl, 2 mM MgCl2, 5 mM EGTA, pH 7.0).
Cells were lysed by four cycles of freezing and thawing followed by
centrifugation (30 min, 13,000 g, 4 °C). To 10 g of cell lysate protein,
80 l assay buffer was added (100 mM HEPES, 10% (w/v) sucrose, 0.1%
(v/v) Nonidet P40, 10 mM dithiothreitol, 25 M acetyl-Asp-Glu-Val-Asp-
7-amino-4-methylcoumarin, pH 7.25), and the release of AMC was
monitored (45 min, 37 °C) in a fluorescence plate reader (HTS 7000
bioassay reader; PerkinElmer Life Sciences). Free AMC was used as a
standard, and caspase activity was expressed as pmol of AMC/min/mg
of protein.
Determination of Mitochondrial Membrane Potential—Mitochondrial
membrane potential was essentially performed as described before (41,
42) with some modifications. Briefly, cells were harvested as described
for AV/PI staining. Following recovery in complete medium, cells were
incubated with 1 M rhodamine 123 (Rho123) and APC-conjugated
annexin V (43) in AV buffer (30 min, 37 °C). Cells were centrifuged (30
s, 400  g, room temperature), and the pellet was resuspended in AV
buffer containing 2 M propidium iodide 1 min prior to analysis by
confocal laser-scanning microscopy (CLSM; Bio-Rad) or flow cytometry.
As an alternative method to determine the mitochondrial membrane
potential, we used DiOC6 (0.1 M) instead of Rho123 (30, 44, 45).
Selective localization of DiOC6 at the mitochondria was confirmed by
CLSM.
Soft Agar Colony Assay—MTLn3 Neo and Bcl-2 cells were treated
with varying concentrations of doxorubicin as described above. After
24 h, cells were trypsinized, and viable cells (trypan blue exclusion)
were counted. Next, 12,500 cells were plated in 1 ml of top agar (0.33%
(w/v) agarose in complete medium in the presence of amphotericin B
(250 ng/ml)) on top of 2.5 ml of bottom agar (0.66% (w/v) agarose in
complete medium in the presence of amphotericin B (250 ng/ml)) in
duplicate in six-well plates, as described by Kiley et al. (35). After 1
week, a top layer of 2.5 ml of bottom agar was added. After 14 days, 150
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l of a 5 g/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide solution in medium was added to the wells, and after overnight
incubation (37 °C), digital images of the wells were taken with a Nikon
CCD camera. Colonies were counted using a particle-counting option in
Image Pro (Media Cybernetics, Silver Spring, MD).
Immunoblotting—Attached cells were scraped in ice-cold TSE (10
mM Tris-HCl, 250 mM sucrose, 1 mM EGTA, pH 7.4, containing 1 mM
dithiothreitol, 10 g/ml leupeptin, 10 g/ml aprotinin, 1 mM sodium
vanadate, 50 mM sodium fluoride, and 1 mM phenylmethylsulfonyl
fluoride). Floating cells in the medium and in one wash of PBS were
pelleted (5 min, 200  g, 4 °C) and pooled with scraped cells in TSE.
The protein concentration in the supernatant was determined using the
Bio-Rad protein assay using IgG as a standard. Fifteen g of total
cellular protein was separated by SDS-PAGE and transferred to poly-
vinylidene difluoride membrane (Millipore Corp., Etten Leur, The
Netherlands). Blots were blocked with 5% (w/v) nonfat dry milk in
TBS-T (0.5 M NaCl, 20 mM Tris-HCl, 0.05% (v/v) Tween 20, pH 7.4) and
probed for Bcl-2 (C-2; Santa Cruz Biotechnology, Inc., Santa Cruz, CA),
p53 (polyclonal antibody 240; Santa Cruz Biotechnology), CD95 (FL335;
Santa Cruz Biotechnology), CD95L (clone 33; Transduction Laborato-
ries), caspase-8 (kindly provided by Prof. J. Borst (46)), active caspase-3
(CM-1; kindly provided by Dr. A. Srinivasan (47)), or protein kinase C
(14K; kindly provided by Dr. S. Jaken (48)), followed by incubation
with secondary antibody containing horseradish peroxidase and visu-
alization with ECL reagent (Amersham Biosciences AB, Uppsala,
Sweden).
Cytosolic Fractions for Cytochrome c Immunoblotting—Cytosolic
fractions were prepared as described by Boesen-de Cock (46). Briefly,
floating cells in the medium and one wash of mitobuffer (50 mM PIPES-
KOH (pH 7.4), 220 mM mannitol, 68 mM sucrose, 50 mM KCl, 5 mM
EGTA, 2 mM MgCl2, 1 mM dithiothreitol, and 1 mM phenylmethylsul-
fonyl fluoride) were pelleted (5 min, 200  g, 4 °C) and pooled with
attached cells scraped in 100 l of ice-cold mitobuffer. Cells were pel-
leted (1 min, 400  g, room temperature), resuspended in 100 l of
mitobuffer, and allowed to swell on ice for 30 min. Cells were homoge-
nized by passing the suspension through a 25-gauge needle (10 strokes).
Homogenates were centrifuged (15 min, 13,000  g, 4 °C), and super-
natants were collected. Thirty g of cytosolic protein was separated on
a 15% SDS-PAGE gel and transferred to polyvinylidene difluoride
membrane. Cytochrome c was detected with anti-cytochrome c mono-
clonal antibody (7H8.2C12; BD PharMingen) using the Western Star
kit (Tropix, Bedford, MA).
Immunocytochemistry—Cells were cultured on 12-mm collagen-
coated glass coverslips and fixated in fresh 4% (w/v) paraformaldehyde
in PBS. Coverslips were blocked in TBP (0.5% (w/v) bovine serum
albumin and 0.05% (v/v) Tween 20 in PBS, pH 7.4) (1 h, room temper-
ature) and subsequently incubated with primary antibody in TBP (1 h,
room temperature). Coverslips were washed twice in PBS containing
0.05% Tween 20 and incubated with AlexaTM 488-, Cy3- or Cy5-conju-
gated secondary antibodies in TBP (45 min, room temperature). After
washing, coverslips were incubated with 2 g/ml Hoechst 33258 in PBS
(15 min, room temperature), washed in PBS, and mounted in Aqua
PolyMount (Polysciences, Warrington, PA). In some experiments, cells
were incubated with 200 nM MitoTracker Red CMXRos in complete
medium (15 min, 37 °C) prior to fixation. Primary antibodies used were
Bcl-2 (C-2; Santa Cruz Biotechnology) and cytochrome c (6H2B4; BD
PharMingen). Imaging occurred by confocal laser-scanning microscopy
(Bio-Rad).
Statistical Analysis—Student’s t test was used to determine whether
there was a significant difference between two means (p  0.05). When
multiple means were compared, significance was determined by one-
way analysis of variance (p  0.05). For analysis of variance analysis,
letter designations are used to indicate statistically significant differ-
ences. Means with a common letter designation within one figure are
not different; those with a different letter designation are significantly
different from all other means with different letter designations. For
example, a mean designated as a is significantly different from a mean
designated b, but neither is different from a mean designated a,b.
RESULTS
Doxorubicin Decreases the  Prior to the Onset of PS Exter-
nalization—The mitochondria are key organelles in the control
of apoptosis. Therefore, we investigated the involvement of
mitochondrial dysfunction in doxorubicin-induced apoptosis.
The  is a sensitive measure for mitochondrial functioning
(reviewed by Kroemer and Reed (49)). Previously, we reported
on the apoptotic effects of doxorubicin on MTLn3 cells (38).
Doxorubicin induced apoptosis in a time-dependent manner, as
determined by annexin V-staining, analysis of DNA content,
and caspase activity. The onset of apoptosis occurred between 8
and 16 h after exposure, with maximal caspase-3 activity at
24 h.
In the present study, we analyzed  after doxorubicin treat-
ment by flow cytometry using Rho123. Initially, Rho123 fluo-
rescence was only quantified in the PI (i.e. viable) population,
gated as indicated in Fig. 1A. Doxorubicin caused a decrease in
 in PI cells (Fig. 1B). PI cells, however, include two cell
populations: genuinely viable cells as well as early apoptotic
cells. These cells can be distinguished by the absence or pres-
ence of externalized PS (viable and apoptotic cells, respectively)
FIG. 1. Doxorubicin-induced loss of
 in nonnecrotic cells. MTLn3 cells
were exposed to 17 M doxorubicin (Dox)
or vehicle for 1 h and subsequently al-
lowed to recover for 24 h in the absence or
presence of 100 M zVAD-fmk.  was
determined by flow cytometry in nonne-
crotic, PI cells (defined as shown in A)
using rhodamine 123 (R123; B and C). In
B, the thick line indicates control cells,
and the dashed line indicates doxorubi-
cin-treated cells. RFU, relative rhoda-
mine 123 fluorescence units; FSC, for-
ward scatter of cells. Data shown are the
mean of three independent experi-
ments  S.E. Lowercase letters indicate
statistical significance as described under
“Experimental Procedures.”
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as identified by annexin V staining. Therefore, the possibility
existed that the drop in  was mainly present in cells that
were already apoptotic (i.e. have externalized PS). Alterna-
tively, apoptotic cells may have a disturbed intracellular dis-
tribution of Rho123 that does not reflect the mitochondrial
membrane potential. To investigate these possibilities in more
detail, MTLn3 cells were stained with Rho123 and propidium
iodide as well as APC-labeled AV. This enabled us to determine
the relationship between loss of  and onset of apoptosis in
PI cells. Using CLSM (Fig. 2), we observed that in control
cells, the Rho123 staining is intense and strictly located at the
mitochondria; little variability is observed between cells (A–C).
In contrast, in doxorubicin-treated cells, there is considerable
variability in Rho123 staining (G–I). Thus, whereas in all AV/
PI cells Rho123 is located at mitochondria, some of these cells
have a markedly decreased . In contrast, in AV/PI cells
the Rho123 staining is more diffuse (asterisks).
Because of the variability in Rho123 staining in AV/PI
cells and the more diffuse localization of Rho123 in AV/PI
cells, we reevaluated the Rho123 fluorescence intensity meas-
urements by flow cytometry. Doxorubicin caused a clear in-
crease in the percentage of AV/PI cells as determined by
three-color flow cytometry with Rho123, PI and APC-annexin V
(Fig. 3, A and B). Moreover, in accordance with the CLSM
observations, the decrease of  caused by doxorubicin was
already present in AV/PI cells (i.e. prior to PS externaliza-
tion) (Fig. 3, C and D). Similar observations were made with
another structurally unrelated fluorescent dye, DiOC6 (Fig. 4),
that is also often used to determine the mitochondrial mem-
brane potential in living cells (30, 44, 45). We also investigated
whether the collapse of  in MTLn3 cells was restricted to
doxorubicin. The anticancer agent etoposide did not induce
dissipation of  under conditions that resulted in comparable
levels of apoptosis (Fig. 3, E and F).
Doxorubicin-induced Dissipation of  Is Independent of
Caspase Activation—Next we wanted to determine the mecha-
nism for the early mitochondrial perturbations in doxorubicin-
induced apoptosis. Up-regulation of CD95/CD95L, which may
occur in a p53-dependent manner, and subsequent activation of
caspase-8 have been implicated in doxorubicin-induced apo-
ptosis (12, 50, 51). Therefore, we examined the kinetics of
expression and/or cleavage of these proteins. Treatment of
MTLn3 cells with doxorubicin rapidly induced up-regulation
of p53, CD95, and CD95L (Fig. 5A). Caspase-8 cleavage was
first observed at 12 h after exposure and may therefore be
responsible for the collapse of the mitochondrial membrane
FIG. 2. Rhodamine 123 staining in the mitochondria decreases in AV/PI cells upon exposure to doxorubicin (Dox). MTLn3 cells
were treated as described in the legend to Fig. 1, harvested as for flow cytometry, and subsequently stained with rhodamine 123 (R123; A, D, G,
and J), annexin V-APC (B, E, H, and K), and PI (C, F, I, and L). Samples were analyzed using CLSM. The asterisks indicate cells that are AV/PI
(i.e. apoptotic) and that display diffuse R123 staining. The arrowheads indicate cells that are AV/PI (i.e. “secondary” necrotic). Data shown are
representative for three independent experiments. Con, control.
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potential. To investigate the involvement of caspases in the
dissipation of , we treated MTLn3 cells with the pancaspase
inhibitor zVAD-fmk. zVAD-fmk protected against doxorubicin-
induced apoptosis (Fig. 3D) and, importantly, abrogated the
cleavage of caspase-8 as well as caspase-3 (Fig. 5B). In contrast,
in the presence of zVAD-fmk, the dissipation of  caused by
doxorubicin in viable cells was also about 35% (Fig. 3D). Also,
evaluation of the intracellular Rho123 localization by CLSM
revealed that the Rho123 distribution within either AV/PI or
AV/PI cells was similar in the absence or presence of zVAD-
fmk (Fig. 2, G and J, asterisks). These combined data indicate
that the decrease in  caused by doxorubicin in viable cells
occurs independent of CD95/CD95L up-regulation and
caspase-8 activation.
Overexpression of Bcl-2 in MTLn3 Cells Inhibits Doxorubi-
cin-induced Apoptosis—If caspases are not involved in doxoru-
bicin-induced collapse of , which pathway(s) may then be
responsible? Antiapoptotic Bcl-2 family members, including
Bcl-2 and Bcl-xL, inhibit apoptosis by preventing mitochondrial
perturbations during the apoptotic process. Therefore, we
tested whether the decrease of  in genuinely viable cells
upon doxorubicin treatment also occurred in MTLn3 cells over-
expressing Bcl-2. We constructed MTLn3 cells stably overex-
pressing Bcl-2 and characterized the protective action of Bcl-2
in doxorubicin-induced apoptosis. Three different clones were
obtained, which all showed strong overexpression of Bcl-2 (Fig.
6A). Immunofluorescent staining for Bcl-2 together with the
mitochondrial marker Mitotracker Red (CMXRos), indicated
that most of the Bcl-2 was located at the mitochondria (Fig.
6A). Very little Bcl-2 staining was detectable in Neo control
cells. In Bcl-2-overexpressing (Bcl-2) cells, doxorubicin did not
induce statistically significant DNA fragmentation at concen-
trations up to 25 M, whereas in Neo control cells 39% apopto-
sis was observed (Fig. 6B). DNA fragmentation is a late, caspase-
dependent event in apoptosis. Therefore, we also determined
the effect of Bcl-2 overexpression on caspase activation. Doxo-
rubicin caused a clear induction of caspase-3-like activity in
Neo cells (156  11 pmol of Asp-Glu-Val-Asp-7-amino-4-meth-
ylcoumarin/min/mg of protein (control) versus 528  76 pmol of
Asp-Glu-Val-Asp-7-amino-4-methylcoumarin/min/mg of pro-
tein (doxorubicin)). Although some induction of caspase activity
was observed in Bcl-2 cells (25  11 pmol of Asp-Glu-Val-Asp-
7-amino-4-methylcoumarin/min/mg of protein (control) versus
120  6 pmol of Asp-Glu-Val-Asp-7-amino-4-methylcoumarin/
FIG. 3. Three-color flow cytometry shows that collapse of  by doxorubicin (Dox) occurs prior to PS exposure. MTLn3 cells were
treated as described in the legend to Fig. 1 or with 50 M etoposide under the same conditions and stained for rhodamine 123 (R123), annexin V,
and PI prior to analysis by flow cytometry. The plots show clear separation of viable (AV/PI; R1), apoptotic (AV/PI; R2), and necrotic (AV/PI;
R3) cells in control (A) and doxorubicin-treated cells (B). The decrease in  is shown as the mean fluorescence intensity of R123 in doxorubicin-
treated (C and D), or etoposide-treated AV/PI cells (E and F). Control samples (Con) are indicated with a thick line (C and E), and doxorubicin
(C) and etoposide (Eto; E) are indicated with a dashed line. The percentage of DNA fragmentation in D and E indicates the percentage of cells with
sub-G1/G0 DNA content as determined by flow cytometric cell cycle analysis. Data shown are the mean of three independent experiments  S.E.
Lowercase letters indicate statistical significance as described under “Experimental Procedures.”
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min/mg of protein (doxorubicin)), the absolute activity was less
than 25% of doxorubicin-treated Neo cells.
In a previous report (38), we demonstrated that inhibition of
caspases using zVAD-fmk did not completely block doxorubi-
cin-induced PS externalization in MTLn3 cells. This indicated
that part of the PS externalization occurred in a caspase-
independent, possibly Bcl-2-sensitive manner. Therefore, we
next investigated whether Bcl-2 was able to block doxorubicin-
induced PS externalization. Whereas inhibition of caspases
reduced DNA fragmentation to control levels in Neo cells (Fig.
7A), PS externalization caused by doxorubicin treatment was
only marginally affected by zVAD-fmk (Fig. 7B). In contrast,
Bcl-2 overexpression protected against DNA degradation as
well as PS externalization induced by doxorubicin (Fig. 7).
zVAD-fmk had only a slight additional protective effect on DNA
fragmentation, but it had no effect on PS externalization. Im-
portantly, whereas the resistance of Bcl-2 cells to doxorubicin
was not due to inhibition of the induction of p53, CD95, or
CD95L expression, caspase-8 and caspase-3 activation were
markedly reduced in Bcl-2 cells (Fig. 7C). The inhibition of
caspase-8 cleavage in Bcl-2 cells further strengthens the notion
that caspase-8 cleavage occurs secondary to mitochondrial per-
turbations. These observations indicate clear differences in the
regulation of several apoptotic features in doxorubicin-induced
apoptosis by Bcl-2 on the one hand and caspases on the other
hand.
Bcl-2 Does Not Protect against Doxorubicin-induced Dissipa-
tion of —In many cell types, Bcl-2-mediated protection
against apoptosis is associated with preservation of mitochon-
drial homeostasis (19). Since Bcl-2 protected against PS exter-
nalization, we next checked whether Bcl-2 could also prevent
the decrease in  induced by doxorubicin as observed in AV/
PI MTLn3 (see Fig. 3, C and D). Flow cytometric analysis
(Rho123, PI, and annexin V-APC staining) of Neo cells indi-
cated that doxorubicin induced a dissipation of  of 60% in
AV/PI cells. Surprisingly, doxorubicin caused a similar dis-
sipation of  in AV/PI Bcl-2 cells (Fig. 8A). The  of
apoptotic AV/PI cells remained unchanged under all condi-
tions in both Neo and Bcl-2 cells (Fig. 8B). As mentioned above,
doxorubicin still caused some activation of caspases in Bcl-2
cells. Therefore, the possibility existed that low caspase activity
contributes to the dissipation of . To exclude this possibility,
both Neo and Bcl-2 cells were treated with doxorubicin in the
presence of zVAD-fmk. Co-incubation with zVAD-fmk did not
affect the doxorubicin-induced decrease of  in both Neo and
Bcl-2 cells. Next we investigated whether these findings are
also applicable to other cells. For this purpose, we used the
immortalized porcine renal proximal tubular epithelial cell line
LLC-PK1 that is also sensitive to doxorubicin (40). As expected,
LLC-PK1 cells stably transfected with Bcl-2 (pkBcl2 clone 6)
were resistant to doxorubicin-induced apoptosis compared with
empty vector control cells (pkNEO clone 1). In addition, cells
that were not yet apoptotic after doxorubicin treatment (e.g.
AV/PI cells) had a decreased  (Table I). zVAD-fmk did
block the doxorubicin-induced apoptosis of pkNEO and pkBcl2
cells; however, no protection was observed against the decrease
FIG. 4. Doxorubicin-induced dissipation of  as determined
by DiOC6 staining. MTLn3 cells were treated with doxorubicin as
described in the legend to Fig. 1 and stained for DiOC6, annexin V, and
PI prior to analysis by flow cytometry as described under “Experimental
Procedures.” Data shown are the mean of three independent experi-
ments  S.E. Characters indicate statistical significance as described
under “Experimental Procedures.”
FIG. 5. Doxorubicin-induced up-regulation of CD95, CD95L,
and p53, which was accompanied by zVAD-fmk-inhibitable
caspase-8 and -3 cleavage. MTLn3 cells were treated with vehicle or
17 M doxorubicin for 1 h and allowed to recover in the absence (A) or
presence (B) of 100 M zVAD-fmk for the indicated times (A) or 24 h (B)
and immunoblotted for CD95, CD95L, caspase-8 (casp-8), p53, and
caspase-3 (casp-3). The arrowheads and double lines indicate the full-
length proteins and cleavage fragments, respectively. Data shown are
representative for three independent experiments.
FIG. 6. Bcl-2 overexpression inhibits doxorubicin-induced ap-
optosis of MTLn3 cells. Neomycin-resistant (Neo) cells and Bcl-2
overexpressing (Bcl-2) cells were subjected to Western blotting and
immunofluorescent staining with a Bcl-2 antibody and mitochondrial
staining using MitoTracker Red (MitoT; A). Neo and Bcl-2 cells were
exposed to the indicated concentrations of doxorubicin for 1 h and
subsequently allowed to recover for 24 h. Apoptosis was determined by
cell cycle analysis (B). Data shown are representative for (A) or the
mean of (B) three independent experiments with three individual
clones  S.E. Characters indicate statistical significance as described
under “Experimental Procedures.”
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of  (Table I). In conclusion, these data indicate that the
dissipation of  caused by doxorubicin is an event that occurs
upstream of a checkpoint controlled by either the Bcl-2 family
or caspases.
Bcl-2 Does Not Protect against Long Term Survival of
MTLn3 Cells after Doxorubicin Treatment—Bcl-2 clearly pro-
tected against doxorubicin-induced apoptosis. However, the
fact that no protection was observed against the doxorubicin-
induced dissipation of the mitochondrial membrane potential
suggested that compromised mitochondrial function may affect
long term survival. Indeed, in MTLn3 cells overexpressing
Bcl-2, doxorubicin still caused a strong reduction in clonogenic
survival in a soft agar assay (Fig. 9).
Cytochrome c Release Is Not Strictly Correlated with Loss of
—Cytochrome c release from the mitochondria is a critical
event in formation of the apoptosome and subsequent activa-
tion of caspase-9 and -3 (6). In our cells, the doxorubicin-
induced loss of  was not inhibited at all by caspase inhibi-
tion. Moreover, Bcl-2 did not protect against the dissipation of
 either. It has been reported that in various models of apo-
ptosis, the protective effect of Bcl-2 occurs through inhibition of
mitochondrial cytochrome c release (52, 53). This suggests that
the loss of , on the one hand, and cytochrome c release with
subsequent caspase-activation, on the other hand, may be in-
dependent events in doxorubicin-induced apoptosis of MTLn3
cells. We first characterized the cytochrome c release in Neo
cells. To investigate the relationship between the loss of  and
cytochrome c release, we used the mitochondrial membrane
potential-sensitive dye CMXRos (54) in combination with im-
munofluorescent staining of cytochrome c. For this purpose,
cells were incubated with CMXRos just prior to fixation of the
cells. This procedure allowed us to evaluate , cytochrome c
localization, and caspase-3 activation in individual attached
cells by CLSM. In Neo control cells, cytochrome c was clearly
visible as a punctate staining that clearly co-localized with
CMXRos, indicating mitochondrial localization (Fig. 10A). Ex-
posure to doxorubicin caused a decreased staining of CMXRos;
in some cells, no mitochondrial localization of CMXRos was
evident (arrowhead). Also, the punctate localization of cyto-
chrome c staining was lost (Fig. 10A, arrowhead and asterisk),
which was evident in15% of the cells (Fig. 10B). To determine
FIG. 8. Bcl-2 does not inhibit loss of  induced by doxorubicin
in MTLn3 cells. The samples shown in Fig. 7, A and B, were also used
for analysis of  using R123 in viable (AV/PI; A) and apoptotic
(AV/PI; B) cells. RFU, relative rhodamine 123 fluorescence units.
Data represent the mean of three independent experiments with three
individual clones  S.E. Lowercase letters indicate statistical signifi-
cance as described under “Experimental Procedures.”
FIG. 7. Differential regulation of
DNA fragmentation and PS external-
ization by Bcl-2 and caspases. Neo and
Bcl-2 cells were treated as described in
the legend to Fig. 1. Apoptosis was deter-
mined by cell cycle analysis (A) and AV/PI
staining (B) in split samples. Western blot
samples were also taken at 12 h (CD95,
CD95L, p53) or 24 h (caspase-8 and -3)
after exposure to 17 M doxorubicin (C).
Data represent the mean of (A, B) or are
representative for (C) three independent
experiments with three individual
clones  S.E.
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whether this cytochrome c translocation correlated with dissi-
pation of , we further discriminated between cells with high
or low . This revealed that cytochrome c release was not
strictly correlated with loss of , since also cells with still high
 showed cytochrome c release, although to a lesser extent
than cells with low  (Table II). In addition, there were also
cells that had almost completely lost  (little or no CMXRos
staining; ) but still showed mitochondrial cytochrome c stain-
ing. The release of cytochrome c as well as the loss of  as
visualized with CMXRos always preceded the onset of caspase
activity; no active caspase-3 staining could be observed in any
of the attached cells after doxorubicin treatment (data not
shown). In contrast, staurosporin (50 nM, 6 h) was capable of
induction of caspase-3 activation prior to cell detachment, prob-
ably due to the rapid induction of apoptosis (data not shown).
Bcl-2 Only Partially Inhibits the Release of Cytochrome c—
Next we investigated the protective role of Bcl-2 against doxoru-
bicin-induced release of cytochrome c. Despite the fact that Bcl-2
protected against apoptosis, doxorubicin induced cytochrome c
release in cells that were still attached to a similar extent in Bcl-2
cells as in Neo cells (Fig. 10, A and B). Also, in Bcl-2 cells there
was no direct correlation between loss of  and cytochrome c
release as in Neo cells (Fig. 10A and Table II). MTLn3 cells that
become apoptotic detach from the substratum. Bcl-2 overexpres-
sion decreased the sensitivity to doxorubicin; therefore, fewer
detached apoptotic cells are found in the medium. Hence, the
percentage of cells with cytochrome c release as judged from the
immunofluorescent staining of attached cells most likely under-
estimates the total extent of cytochrome c release. This is pre-
dominantly the case for Neo cells. For this reason, we also eval-
uated the total mitochondrial cytochrome c release in the pooled
floating and attached cells using Western blotting (Fig. 10C). No
cytochrome c release was observed in untreated cells. However,
doxorubicin clearly increased the extent of cytochrome c release
in Neo cells, which was already evident after 16 h. Although in
some Bcl-2 cells, cytochrome c release was observed after doxo-
rubicin treatment at both 16 and 24 h, the levels were consider-
ably lower than for the Neo cells.
In conclusion, these combined data indicate that loss of  is
not necessarily preceded by cytochrome c release and that Bcl-2
is unable to completely prevent cytochrome c release and loss of
 in viable cells. However, Bcl-2 decreases the extent of ap-
optosis although it cannot completely prevent cytochrome c
release. This suggests that commitment to apoptosis, at least in
part, occurs downstream of cytochrome c release.
DISCUSSION
Our investigations on the sequence of several critical mito-
chondria-related events in doxorubicin-induced apoptosis in
mammary adenocarcinoma cells allow several conclusions.
First, we found that the dissipation of the  in doxorubicin-
induced apoptosis precedes PS externalization in these cells.
Importantly, this loss of  is caspase-independent. Therefore,
mitochondrial changes resulting in collapse of  appear to be
a primary event preceding caspase activation. Second, al-
though overexpression of Bcl-2 protected against caspase acti-
vation, PS externalization, and DNA fragmentation, Bcl-2 did
not prevent the loss of  caused by doxorubicin. Nevertheless,
Bcl-2 inhibited the release of cytochrome c from the mitochon-
dria to a large extent. Third, detailed analysis of the relation-
ship between the dissipation of  and cytochrome c release
indicated that these events are mutually independent in both
normal cells and cells that overexpress Bcl-2. Altogether, these
data indicate that doxorubicin causes a dissipation of the mi-
tochondrial membrane potential, which is independent of Bcl-2
or caspase-controlled pathways.
Our data indicate that loss of  occurs early in doxorubicin-
induced apoptosis in MTLn3 cells as well as in LLC-PK1 cells.
This occurs well before cell death (i.e. in PI cells) and PS
externalization, an early event generally associated with the
onset of apoptosis (55, 56). In other studies, this could not be
established, because the  in doxorubicin-treated cells was
determined in a heterogeneous population of cells, containing,
besides genuinely viable cells, apoptotic or even necrotic cells,
which have no functional mitochondria (30–33). Thus, in an-
other study, only the time course of either loss of  or annexin
V binding was studied independently in doxorubicin-induced
apoptosis (29). As a consequence, these studies did not make
proper distinctions between the population of cells: genuinely
viable cells, early apoptotic cells (i.e. with externalized PS), or
TABLE I
Effect of Bcl-2 overexpression on doxorubicin-induced apoptosis and loss of  in LLC-PK1 cells
pkNEO and pkBCL-2 cells were treated with varying concentrations of doxorubicin in the absence or presence of z-VAD-fmk (100 M) in
Dulbecco’s modified Eagle’s medium containing penicillin/streptomycin for 24 h. Thereafter, total percentage of cell death (AV/PI and AV/PI)
and  were determined as described under “Experimental Procedures.” Data shown are the mean S.E. of three independent experiments. RFU,
relative rhodamine 123 fluorescence units.
Cell death  AV/PI (Rho123)
pkNEO pkBCL-2 pkNEO pkBCL-2
% %
Control 15  1 13  1 189  25 (100)a 177  22 (100)
Doxorubicin, 2.5 M 42  4 24  1 129  29 (68) 100  12 (57)
Doxorubicin, 5 M 49  2 33  4 128  27 (76) 85  12 (48)
zVAD 14  1 12  1 192  23 (101) 176  21 (100)
zVAD/doxorubicin, 5 M 12  1 13  1 86  12 (45) 45  12 (25)
a Numbers in parentheses are the percentage  of control.
FIG. 9. Bcl-2 is unable to prevent the inhibition of colony for-
mation of MTLn3 cells by doxorubicin. Both Neo- and Bcl-2-MTLn3
cells were treated with doxorubicin and plated in soft agar as described
under “Experimental Procedures.” Colony formation is expressed as the
percentage of each vehicle-treated cell line. Untreated Bcl-2 cells grew
slightly slower than Neo cells (747  61 and 862  82 colonies/well,
respectively). Data shown are the mean of three independent experi-
ments with three Neo and Bcl-2 clones  S.E.
Bcl-2 Regulation of Mitochondrial Dysfunction and Apoptosis35876
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 3, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
necrotic cells, in which loss of  occurred. Since we have used
confocal microscopy and three-color flow cytometry, we could
show that mitochondrial changes are a primary event in doxo-
rubicin-induced apoptosis that occurs already in AV/PI cells.
Moreover, this loss of  is not inhibited by the pancaspase
inhibitor zVAD-fmk. Fulda et al. (31) reported that in SHEP
neuroblastoma cells zVAD-fmk blocked doxorubicin-induced
collapse of . In this study, however, dissipation of  was
determined in the total cell population so that necrosis may
have contributed to the observed loss of . The only study to
our knowledge that combined annexin V staining with a mito-
chondrial membrane potential-sensitive dye (but not PI),
showed that etoposide-induced loss of  in PC60 cells was
preceded by PS externalization (33). In contrast, we showed
that etoposide did not affect the mitochondrial membrane po-
tential in viable MTLn3 cells (Fig. 3, E and F).
Three main pathways for anticancer agent-induced mito-
chondrial perturbations have been proposed. First, an indirect
pathway, which is largely dependent on DNA-damage and/or
stress signaling, may result in up-regulation of the death re-
ceptor pathway. Activation of caspase-8 is a primary event in
CD95 signaling. If this pathway is involved in doxorubicin-
induced mitochondrial perturbation, then inhibition of
caspases should prevent this (10–12). Second, cellular damage
may also result in up-regulation or posttranslational modifica-
tion of several proapoptotic Bcl-2 family members that directly
affect mitochondrial membrane integrity (e.g. Bax up-regula-
tion and translocation to the mitochondria or Bad phosphoryl-
ation) (57–59). The consensus is that this pathway acts inde-
pendent of caspase-8 activation and is generally inhibited by
Bcl-2 overexpression (20). Third, the effect of doxorubicin in
MTLn3 cells may be a direct effect of doxorubicin on the mito-
chondria, as has been observed in isolated mitochondria from
heart and liver (28, 60).
CD95 activation would exert its effect through caspase-8
activation and Bid cleavage, which may engage the mitochon-
dria. In MTLn3 cells, doxorubicin caused up-regulation of
CD95 and CD95L. However, since zVAD-fmk prevented
caspase-8 activation (Fig. 5B) without affecting the mitochon-
drial perturbations, the CD95/CD95L/caspase-8 pathway plays
a minor role in the observed loss of . The fact that zVAD-fmk
does not inhibit the dissipation of  also argues against a
feedback mechanism in which a moderate release of cyto-
chrome c would activate caspase-3, which in turn affects the
mitochondria, thereby enhancing loss of  and/or further re-
lease of cytochrome c (61–63).
Overexpression of Bcl-2 and Bcl-xL inhibits apoptosis in-
duced by a variety of stimuli, in particular those that utilize the
mitochondria-dependent pathway (20, 64). This is often asso-
ciated with protection against the release of cytochrome c as
well as collapse of  (52, 53, 65). The Bcl-2-mediated protec-
tion of mitochondria is most likely due to the prevention of pore
opening caused by Bax- or Bak-dependent mechanisms. We
show that in MTLn3 cells that overexpress Bcl-2, mitochon-
drial changes including loss of  and a moderate cytochrome
c release still occur upon doxorubicin treatment. This implies
that the doxorubicin-induced loss of  is most likely not
caused by proapoptotic Bcl-2 family members. Similar effects
have been observed in HL60 cells treated with carbonyl cyanide
m-chlorophenylhydrazone. However, since carbonyl cyanide m-
chlorophenylhydrazone uncouples mitochondrial respiration,
Bcl-2 could not prevent a decrease in  or cytochrome c re-
lease, despite inhibition of apoptosis (66).
Which possible pathways may then cause dissipation of 
by doxorubicin in MTLn3 cells? One possibility is that doxoru-
bicin exerts its effect on the mitochondria through the up-
regulation of p53 (67). Doxorubicin clearly increased the levels
of p53 in MTLn3 cells. As was to be expected, the Bcl-2-medi-
ated protection against apoptosis did not occur through a re-
duction in doxorubicin-induced DNA damage, since the up-
regulations of p53 and G2/M arrest were similar in Neo and
Bcl-2 cells (Fig. 7C and data not shown). Moreover, the expres-
FIG. 10. Cytochrome c release and
loss of  are independent events in
Neo and in Bcl-2 MTLn3 cells. Neo and
Bcl-2 cells were grown on glass coverslips
and treated with 17 M doxorubicin or
vehicle and recovered for 24 h (or 16 h; C).
Cells were labeled with Mitotracker prior
to fixation, stained for cytochrome c, and
analyzed by confocal microscopy (A).
These cells were also counted (	100 cells/
experiment) for cytochrome c staining,
and the percentage of cytochrome c-nega-
tive cells is expressed in B. Alternatively,
cytosolic fractions were analyzed by West-
ern blotting for cytochrome c as described
under “Experimental Procedures” (C).
Data shown are representative for (A and
C) or the mean of (B) three independent
experiments with three individual
clones  S.E. Lowercase letters indicate
statistical significance as described under
“Experimental Procedures.”
TABLE II
Cytochrome c release in MTLn3 cells with high or low 
Neo and Bcl-2 MTLn3 cells were treated as described in the legend to
Fig. 7. The percentage of cytochrome c-negative cells in cells with high
and low  is expressed. Data shown are mean  S.E. of three inde-
pendent experiments (	100 cells/sample).
Cytochrome c-negative cells
Neo Bcl-2
Control Doxorubicin Control Doxorubicin
% % % %
Low  2.5  0.5 10.5  3.0 2.3  0.3 7.5  2.4
High  2.2  0.9 4.8  0.8 2.4  1.0 6.7  1.8
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sion levels of CD95 and CD95L were also similar in Neo and
Bcl-2 cells. Thus, either p53 or other p53-regulated genes that
reside in the mitochondria or translocate there during apopto-
sis may cause perturbations of the mitochondria, e.g. by induc-
tion of reactive oxygen species (68–71). Alternatively, we can-
not exclude the possibility that doxorubicin has a direct effect
on the mitochondria.
Regardless of the mechanism of loss of , the question
remains whether collapse of  is causally linked to doxorubi-
cin-induced cytochrome c release. Several findings indicate
that this may not be the case. First, at the cellular level there
are cells, which (i) have a low  and normal mitochondrial
staining of cytochrome c, (ii) have a high  but no mitochon-
drial staining of cytochrome c, or (iii) have neither  nor
mitochondrial staining of cytochrome c (Fig. 10A). Second,
Bcl-2 largely inhibits cytochrome c release, although it is un-
able to prevent doxorubicin-induced collapse of . This is in
agreement with previous observations that cytochrome c re-
lease can occur prior to loss of  (32, 44). Together, these
results strongly suggest that the doxorubicin-induced cyto-
chrome c release and collapse of  are mutually independent
events.
Our data indicate that Bcl-2 was able to inhibit doxorubicin-
induced apoptosis despite the fact that some cytochrome c
release was observed at 16 h after exposure. This appears to be
comparable with the observation that Bcl-2 overexpression
markedly reduced apoptosis caused by microinjection of cyto-
chrome c. Such an effect may be mediated by sequestration of
procaspase-9 by Bcl-2, thereby inhibiting formation of the ap-
optosome and activation of caspase-3 (72–77).
In MTLn3 cells, Bcl-2 overexpression clearly protected
against doxorubicin-induced DNA fragmentation as well as PS
externalization. Interestingly, zVAD-fmk only partially pro-
tected against PS externalization (38). This strongly suggests
that PS externalization caused by doxorubicin is largely caused
by a caspase-independent pathway that is inhibitable by Bcl-2.
The fact that Bcl-2 does not inhibit loss of  further indicates
that the PS externalization is not a consequence of dissipation
of the mitochondrial electrochemical gradient. Alternatively,
Bcl-2-mediated protection against pore formation and/or outer
membrane rupture may prevent the release of unknown mito-
chondrial factors that induce PS externalization.
In conclusion, our data provide the following model for doxo-
rubicin-induced apoptosis. Doxorubicin causes cellular stress,
resulting in p53 up-regulation/accumulation and increased lev-
els of CD95 and CD95L. In addition, doxorubicin causes mito-
chondrial injury, which appears to be independent of the CD95/
CD95L/caspase-8 pathway. Although Bcl-2-dependent events
and caspase activation are required for the induction of apop-
tosis, the dissipation of  caused by doxorubicin is independ-
ent of a caspase- or Bcl-2-controlled pathway. Further studies
are required to elucidate the potential role of p53-dependent
pathways in the observed disruption of .
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